Quick Answer
Nuvation Bio Inc. reported Net Income Loss of -$204.63 million for the year ending 2025.
- Nuvation Bio Inc. showed an increase of +64.0% in Net Income Loss from 2024 to 2025.
- This data is from Nuvation Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$8.75 million | Q2 2020: -$8.60 million | Q3 2020: -$11.03 million | Q1 2021: -$20.40 million | Q2 2021: -$19.33 million | Q3 2021: -$21.98 million | Q1 2022: -$21.29 million | Q2 2022: -$34.86 million | Q3 2022: -$27.20 million | Q1 2023: -$21.73 million | Q2 2023: -$20.64 million | Q3 2023: -$19.65 million | Q1 2024: -$14.79 million | Q2 2024: -$462.49 million | Q3 2024: -$41.21 million | Q1 2025: -$53.24 million | Q2 2025: -$59.01 million | Q3 2025: -$55.79 million.
- Over the full 6 years of available data (2020 to 2025), Nuvation Bio Inc.'s Net Income Loss has declined by 391.2%.
- Historical annual values: Fiscal year 2025: -$204.63 million | Fiscal year 2024: -$567.94 million | Fiscal year 2023: -$75.80 million | Fiscal year 2022: -$104.20 million | Fiscal year 2021: -$86.85 million | Fiscal year 2020: -$41.66 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: